Unclaimed brand
MIRA1a is being developed as the first prescription marijuana drug to treat anxiety and chronic pain.
Liking this brand profile? Share this page
Hex Code
Color name
RGB
HSL
CMYK
#E5B922
Fuel Yellow
229, 185, 34
46, 79, 52
0, 19, 85, 10
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
#0C0C0C
Cod Gray
12, 12, 12
0, 0, 5
0, 0, 0, 95
MIRA Pharmaceuticals, Inc. (MIRA) is a preclinical-stage pharmaceutical company specializing in the development and commercialization of innovative synthetic cannabinoid analogs. We are dedicated to providing effective treatments for adult patients experiencing anxiety, cognitive decline, and neuropathic pain associated with early-stage dementia.
Our key candidate, MIRA1a, has the potential to revolutionize the field of neuropsychiatric, inflammatory, and neurologic diseases and disorders. If approved by the FDA, MIRA1a will be a groundbreaking drug that targets the body's endocannabinoid system with a single molecule, derived from marijuana. This molecule holds promise as a therapeutic solution for a range of debilitating conditions.
At MIRA, we prioritize scientific excellence and collaboration. Our team consists of top scientists, doctors, researchers, and business executives who work together to advance our research and discovery efforts. By continually expanding our clinical and scientific talent, we ensure the highest quality of evaluation, innovation, and support for our groundbreaking work.
Trust MIRA Pharmaceuticals to unlock the full potential of cannabinoid-based therapies and improve the lives of patients worldwide
Company type
Public Company
Year founded
2022
Company size
2-10 employees
Oral cannabinoid therapeutics
CB1 and CB2 receptor targeting
Neurologic and neuropsychiatric disorders
Ketamine-based drug candidates
Clinical-stage pharmaceutical R&D
